| Literature DB >> 31833544 |
Jodie Ouahed1, Elizabeth Spencer2, Daniel Kotlarz3, Dror S Shouval4, Matthew Kowalik1, Kaiyue Peng1,5, Michael Field1, Leslie Grushkin-Lerner1, Sung-Yun Pai6, Athos Bousvaros1, Judy Cho7, Carmen Argmann8, Eric Schadt8,9, Dermot P B Mcgovern10, Michal Mokry11, Edward Nieuwenhuis11, Hans Clevers12, Fiona Powrie13, Holm Uhlig14, Christoph Klein4, Aleixo Muise15, Marla Dubinsky2, Scott B Snapper1.
Abstract
Very early onset inflammatory bowel disease (VEO-IBD) is defined as IBD presenting before 6 years of age. When compared with IBD diagnosed in older children, VEO-IBD has some distinct characteristics such as a higher likelihood of an underlying monogenic etiology or primary immune deficiency. In addition, patients with VEO-IBD have a higher incidence of inflammatory bowel disease unclassified (IBD-U) as compared with older-onset IBD. In some populations, VEO-IBD represents the age group with the fastest growing incidence of IBD. There are contradicting reports on whether VEO-IBD is more resistant to conventional medical interventions. There is a strong need for ongoing research in the field of VEO-IBD to provide optimized management of these complex patients. Here, we provide an approach to diagnosis and management of patients with VEO-IBD. These recommendations are based on expert opinion from members of the VEO-IBD Consortium (www.VEOIBD.org). We highlight the importance of monogenic etiologies, underlying immune deficiencies, and provide a comprehensive description of monogenic etiologies identified to date that are responsible for VEO-IBD.Entities:
Keywords: monogenic etiologies; primary immune deficiency; very early onset inflammatory bowel disease
Mesh:
Year: 2020 PMID: 31833544 PMCID: PMC7216773 DOI: 10.1093/ibd/izz259
Source DB: PubMed Journal: Inflamm Bowel Dis ISSN: 1078-0998 Impact factor: 5.325